CD80 and melanoma: Next, multiplex immunohistochemistry (MxIHC) and whole-tumor imaging spatial analyses were performed on these tumor sections to determine the composition and location of immune cells (e.g., CD8+ T cells and CD11c+ dendritic cells [DC]) in close proximity to SOX10+ melanoma cells in parallel with an assessment of expression of markers for tumor immune surveillance mechanisms (e.g., costimulatory molecules CD40 and CD80 for immune cell activation5,6), or association with clinical parameters pre- and post-treatment (Fig. 1).